Celgene buying T-cell tech partner Juno for $9bn

By Dan Stanton

- Last updated on GMT

Gettyimages/CIPhotos
Gettyimages/CIPhotos

Related tags: T cell receptor

Celgene will add chimeric antigen receptor (CAR) and T-cell receptor (TCR) technologies through the acquisition of its immune-oncology partner Juno Therapeutics.

Celgene confirmed speculation it was buying Juno yesterday by announcing the two firms had come to an agreement to merge.

New Jersey-based Celgene will pay around $9bn (€7.4bn) for the firm, net of the nine million Juno shares it already owns in the company, valued at approximately $800m.

The firms have been working together since July 2015​ when they entered into a 10-year immunotherapy partnership, valued at around $1bn.

Full ownership will place Celgene “at the forefront of future advances in the science of cellular immunotherapy,”​ the company said.

Along with autologous CAR T-cell pipeline boosts in the way of early-phase candidates JCAR017 for non-Hodgkin lymphoma (NHL) and JCARH125 for multiple myeloma, Celgene will add Juno’s scientific platform and scalable manufacturing technologies to its cell therapy capabilities.

This includes cell selection and activation capabilities, and manufacturing automation technologies Juno picked up from German biotech Stage Cell Therapeutics GmbH ​in 2015.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Related suppliers

Follow us

Products

View more

Webinars